{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 is the causal gene for autosomal dominant familial Parkinson’s disease. The I2020T mutation in LRRK2 exhibits higher susceptibility to post-translational degradation than wild-type LRRK2, impairing its protective effect against apoptosis.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly links the I2020T mutation to increased intracellular degradation of LRRK2, which reduces its ability to protect against apoptosis, a key mechanism in Parkinson’s disease neurodegeneration."
        },
        {
          "step_name": "Step 2: Applicability of the assay",
          "extracted_paper_info": "The study uses proteolysis inhibitors to rescue the protective effect of I2020T mutant LRRK2 and compares it to wild-type LRRK2 knockdown experiments.",
          "judgment": "Yes",
          "reasoning": "The assays (proteolysis inhibition, knockdown) are directly relevant to the disease mechanism (loss of function due to degradation)."
        },
        {
          "step_name": "Step 3a: Basic controls/replicates",
          "extracted_paper_info": "The paper compares I2020T mutant to wild-type LRRK2 but does not explicitly mention controls like 'known loss-of-function' or 'gain-of-function' variants, nor does it state multiple replicates.",
          "judgment": "No",
          "reasoning": "While the study compares mutant and wild-type, it lacks explicit documentation of controls or replicates as required for full Step 3a compliance."
        },
        {
          "step_name": "Step 3b: Accepted/validated assay",
          "extracted_paper_info": "The use of proteolysis inhibitors and knockdown experiments are standard techniques in the field.",
          "judgment": "Yes",
          "reasoning": "The assays are historically accepted and validated in the field, satisfying Step 3b criteria."
        },
        {
          "step_name": "Step 3c: Variant controls",
          "extracted_paper_info": "No variant controls (e.g., known pathogenic/benign variants) are explicitly mentioned as part of the study.",
          "judgment": "No",
          "reasoning": "The absence of variant controls means Step 3c criteria are not met."
        },
        {
          "step_name": "Step 4a: Statistical analyses",
          "extracted_paper_info": "The paper does not report statistical tests (e.g., p-values, OddsPath) or quantitative measures of pathogenicity likelihood.",
          "judgment": "No",
          "reasoning": "Statistical analyses or OddsPath values are not reported, so Step 4a is not applicable."
        },
        {
          "step_name": "Step 4b: No OddsPath calculation",
          "extracted_paper_info": "The paper does not specify the number of benign/pathogenic control variants used in the study.",
          "judgment": "N/A",
          "reasoning": "Insufficient information to determine the number of controls for Step 4b."
        }
      ],
      "final_assessment": {
        "functional_evidence_strength": "PS3_supporting",
        "reasoning": "The I2020T mutation’s increased degradation and loss of protective function against apoptosis directly support pathogenicity. While controls/replicates are not fully documented, the assays are validated in the field, leading to PS3_supporting."
      }
    }
  ]
}